Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
RGB 03
(rituximab biosimilar) /
Stada, Gedeon Richter
Welcome,
Profile
Billing
Logout
0 Diseases
0 Trials
0 Trials
2 News
||||||||||
Truxima
(rituximab biosimilar) /
Teva, Mundipharma, Celltrion, Nippon Kayaku, Indukern, Servier
[VIRTUAL] REAL WORLD CLINICAL EFFECTIVENESS AND SAFETY OF CT-P10 IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY
() - May 13, 2021 - Abstract #EHA2021EHA_1076;
Over three quarters of patients initiated on CT-P10 achieved complete or partial response by 30 months, with CT-P10 appearing to be generally well tolerated by patients. The response and survival rates and overall safety profile for CT-P10 appear consistent with those reported for reference rituximab, supporting CT-P10 use in combination with chemotherapy as a therapeutic option for DLBCL.
||||||||||
RGB 03
(rituximab biosimilar) /
Stada, Gedeon Richter
New P1 trial:
Comparative Pharmacokinetic Trial of RGB-03 and MabThera
(clinicaltrials.gov) - Feb 26, 2015
P1
, N=0, Not yet recruiting,
Sponsor: Gedeon Richter Plc.